Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dermata Therapeutics, Inc. (DRMA : NSDQ)

• Company Description    Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $1.21 Daily Weekly Monthly 20 Day Moving Average: 2,390,798 shares Shares Outstanding: 2.84 (millions) Market Capitalization: $3.43 (millions) Beta: 0.50 52 Week High: $10.84 52 Week Low: $1.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.31% 8.91% 12 Week -46.46% -43.05% Year To Date -47.85% -45.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3525 DEL MAR HEIGHTS ROAD SUITE 322 - SAN DIEGO,CA 92130 USA ph: 858-800-2543 fax: - sproehl@dermatarx.com http://www.dermatarx.com

• General Corporate Information    Officers Gerald T. Proehl - President; Chief Executive Officer and Chairman Kyri K. Van Hoose - Chief Financial Officer Wendell Wierenga - Director Mary Fisher - Director Andrew Sandler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 249845504 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/13/26 Share - Related Items Shares Outstanding: 2.84 Most Recent Split Date: 8.00 (0.10:1) Beta: 0.50 Market Capitalization: $3.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 7.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - -130.89 09/30/25 - -191.95 ROA 03/31/26 - - 12/31/25 - -102.20 09/30/25 - -140.15 Current Ratio 03/31/26 - - 12/31/25 - 4.80 09/30/25 - 4.56 Quick Ratio 03/31/26 - - 12/31/25 - 4.80 09/30/25 - 4.56 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 2.19 09/30/25 - 4.69 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©